2023. Lebrikizumab Provides Rapid Response in EASI Components and Itch in Moderate-to-Severe Atopic Dermatitis. SKIN The Journal of Cutaneous Medicine. 7, 6 (Nov. 2023), s279. DOI:https://doi.org/10.25251/skin.7.supp.279.